Skip to content
Medical Health Aged Care

Embedding Genomic Research in Cancer Clinical Trials

Cancer Australia 2 mins read

The Albanese Labor Government is taking a significant step forward in cancer research and care by establishing the Cancer Genomics Clinical Trials Fund to drive advancements in genomic medicine and ensure equitable access to cancer clinical trials incorporating genomics.

This initial $3 million investment will be open to Australia's 14 Multi-site Collaborative Cancer Clinical Trials Groups as part of the Support for Cancer Clinical Trials (SCCT) program. This new Fund is a significant first step in implementing the National Framework for Genomics in Cancer Control, addressing key objectives for genomics-informed diagnosis, treatment, clinical trials, research and data.

The Cancer Clinical Trials Groups, which develop investigator-initiated cancer clinical trials independent of industry, focus on areas of unmet need. By funding these groups, the Cancer Genomics Clinical Trials Fund aims to deliver the actions outlined in the Genomics Framework, in line with the SCCT program objectives. It will foster innovation in clinical trial design, using genomics and molecular targeting techniques, accelerating the translation of genomic medicine into clinical practice.

Consultation with the Cancer Clinical Trials Groups is underway to ensure the design of the Fund is robust and aligned with sector needs. This collaborative approach will help maximise the impact of this investment on cancer research and patient outcomes.

It is important that all Australians have equitable access to genomic medicine. This is not the case for many including those from underserved populations.  The Cancer Genomics Clinical Trials Fund is a new opportunity to progress advancements in genomic medicine and ensure equitable access to cancer clinical trials incorporating genomics.

Quotes attributable to Mark Butler, Minister for Health and Aged Care

"We are living through a supercharged period of discovery that promises to extend the health and wellbeing of Australians, and the Australian Government is proud to fund this important work."

“The Cancer Genomics Clinical Trials Fund demonstrates our commitment to harnessing the power of genomics to revolutionise cancer care for all Australians. By supporting innovative research and clinical trials, we are paving the way for more personalised and effective cancer treatments, offering new hope to patients across the country.”

Quotes attributable to Professor Dorothy Keefe, CEO Cancer Australia

Genomics is a rapidly advancing field, and by embedding genomics into clinical trials, we can enhance our understanding of cancer and potentially offer new management options for patients. This approach may be particularly valuable when exploring treatments for those who have not responded to existing therapies or are waiting for new treatments to become available.”

“Collaboration with the sector will ensure the Cancer Genomics Clinical Trials Fund's investment in genomic medicine translates into the greatest possible impact and real benefits for patients.”


Media Contact:

[email protected]

0438 209 833

More from this category

  • Community, Medical Health Aged Care
  • 08/12/2025
  • 04:15
Save Our Sons Duchenne Foundation

Global Clinical Experts Gather in Sydney to Advance Adult Duchenne Muscular Dystrophy Care

Key Facts: Life expectancy for Australians living with DMD have increased from 18 for those borne before 1970, to around 30 today. As adult care remains fragmented and inconsistent between hospitals and States, the Symposium will develop global multi-disciplinary care recommendations.MEDIA RELEASE A world-first International Symposium dedicated toimproving multi-disciplinary clinical care for adults living with Duchenne muscular dystrophy (DMD) will take place in Sydney over the next three days. Hosted by the Save Our Sons Duchenne Foundation, the invitation-only event will bring together more than 35 of the world’s leading clinicians and researchers to develop the first multidisciplinary, global best-practice…

  • Contains:
  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.